pharma · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Paroxysmal Nocturnal Haemoglobinuria (PNH) · AKTX
Akari Therapeutics
Akari Therapeutics Plc
Akari Therapeutics is a pharma organization headquartered in London, GB. It trades on NYSE under ticker AKTX. Primary therapeutic focus areas include Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Haemog
London, GB HQ
16 Employees
Public company Type
AKTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- London, GB
- Employees
- 16
- Programs
- 9
- Drugs
- 0
- Patents
- 0
MRX-6
Phase 2 · small molecule · Atopic Dermatitis
MRX-6 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Akari Therapeutics Plc with 1 ClinicalTrials.gov record(s).
Internal code C012013
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Akari Therapeutics Plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Atopic Dermatitis
- Status
- terminated
- Trials
- 1